The cost of the opioid epidemic has grown substantially and is estimated to reach over $200 billion, including approximately $66 billion in excess healthcare costs by 2020. As the number one source for teen drug abuse and initiation in the country, pilfering – sneaking just a few pills at a time in secret – is a meaningful component at over $3 billion annually.
After reduced prescribing, dispensing controlled substances in Locking Prescription Vials (LPVs) is the earliest intervention tool aimed at reducing population costs. By preventing initiation on the front-end at an extremely low cost, Locking Prescription Vial (LPV) dispensing can generate substantial financial returns to the healthcare ecosystem players (including payers, plan sponsors and health systems) seeking to reduce/ minimize growth in higher cost patient populations.
Substantial Return on Implementation
The average opioid abuser costs a private sector payer up to $20,000 annually in excess treatment costs, before including the hidden downstream costs of abuse.
By preventing initiation and growth in a high cost patient population, Locking Prescription Vials (LPVs) generate significant cost savings with immediate payback.
High Prevention Impact: 21 Million People Aged 12 – 25
Pilfering, sneaking a few pills at a time in secret, is the #1 Source for teen drug abuse in the U.S. By eliminating pilfering as a source of initiation, Locking Prescription Vial (LPV) dispensing for opioids would prevent approximately 7 million 12 – 17-year-olds and another 14 million 18 – 25-year-olds from initiating abuse over a 10 year period. Locking Prescription Vials (LPVs) protect our children and families from the dangers of addiction and keep dangerous drugs out of our schools.